Evolvere BioSciences

Making Next-Generation Antibiotics that Outpace Bacterial Evolution

Oxford, United Kingdom · Founded 2021 · $500K raised

Headquarters
Oxford
Employees
1–10
Founded
2021
Total Funding
$500K
Last Round
$500K SeedSep 2024
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 1 funding round and 2 investors for this company. The full record is or through the API.

About

🦠🤖 We use our computational models to make next-generation antibiotics that outcompete bacterial evolution and precisely target pathogenic bacteria, without harming good microbes or human cells. ☠️ Current antibiotics stop working because bacteria evolve resistance to them. This makes drug-resistant bacteria a looming global health crisis - already killing more people than malaria and AIDS and it is getting exponentially worse 📈. 🧬 Our approach leverages co-evolutionary protein-protein interaction datasets combined with AI to forecast bacterial mutations and create ‘future-proof’ antibiotics, addressing antibiotic resistance before it develops. This changes the game for how frequently society will need to make new antibiotics and how long our new antibiotics will be able to treat patients 👩‍⚕️. We are a team of biochemists and evolutionary biologists who met at the University of Oxford.

Summary

Evolvere BioSciences is an Artificial Intelligence company based in Oxford, United Kingdom, founded in 2021. It has raised $500K in total across 1 round, most recently a $500K Seed round in Sep 2024. Investors include Y Combinator and Cleo Capital.

Tech & App Stack

10 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

SeedSeed RoundSep 2024
$500K

Investors

Similar Companies

AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Devoted Health

Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...

Waltham, United States1001–5000Artificial Intelligence, Healthcare
Series G+Total funding$3.5BOct 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Evolvere BioSciences on Indexed.vc
<a href="https://indexed.vc/companies/evolvere-biosciences"><img src="https://indexed.vc/api/badge/company/evolvere-biosciences" alt="Evolvere BioSciences on Indexed.vc" width="260" height="76" /></a>